Cross-Resistance between Clofazimine and Bedaquiline through Upregulation of MmpL5 in Mycobacterium tuberculosis

The antileprosy drug clofazimine is also of interest for the treatment of multidrug-resistant tuberculosis. To understand possible resistance mechanisms, clofazimine-resistant Mycobacterium tuberculosis mutants were isolated in vitro, and, unexpectedly, found to be cross-resistant to bedaquiline. Mutations in the transcriptional regulator Rv0678, with concomitant upregulation of the multisubstrate efflux pump, MmpL5, accounted for this cross-resistance. Mutation in Rv0678 should therefore be considered a confounding factor for the treatment of tuberculosis with clofazimine or bedaquiline.


Published in:
Antimicrobial Agents And Chemotherapy, 58, 5, 2979-2981
Year:
2014
Publisher:
Washington, Amer Soc Microbiology
ISSN:
0066-4804
Laboratories:




 Record created 2014-05-26, last modified 2018-03-17


Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)